Stay updated with breaking news from Ionis Core. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First Trust Advisors LP lowered its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 14.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,780,933 shares of the company’s stock after selling 296,327 shares during the period. […]
Tweedy Browne Co LLC raised its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 30.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,541,136 shares of the company’s stock after buying an additional 818,148 shares during the quarter. Ionis Pharmaceuticals accounts for […]
Arizona State Retirement System boosted its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 3.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 36,047 shares of the company’s stock after acquiring an additional 1,367 shares during the quarter. […]
VNET Group restated their maintains rating on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) in a research note released on Thursday, Benzinga reports. IONS has been the subject of several other research reports. Citigroup raised Ionis Pharmaceuticals from a sell rating to a neutral rating and raised their price target for the stock from […]
Citigroup upgraded shares of Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) from a sell rating to a neutral rating in a research report released on Thursday morning, The Fly reports. The firm currently has $36.00 price objective on the stock, up from their previous price objective of $30.00. A number of other brokerages also recently weighed […]